Loading
A phase 3 trial of Savolitinib and Sunitinib in renal cell carcinoma, run by AstraZeneca, active and no longer recruiting.
Savolitinib vs. Sunitinib in MET-driven PRCC. is a phase 3 interventional study registered as NCT03091192 by AstraZeneca, with 60 participants enrolled, started 2017-07-25 and due to reach its primary completion in 2019-08-18. Interventions recorded: Savolitinib and Sunitinib. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
60 enrolled.
95% CI 2.8 to NA; Figures from the ClinicalTrials.gov results section (first posted 2020-07-10), not from a publication · 95% CI 4.1 to 6.9
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)primary | Savolitinib QD | 33 | 7 months | 0.71 (0.37 to 1.36) | 0.313 | link |
| Sunitinib QD | 27 | 5.6 months |
Shares PRCC, Savolitinib, Papillary renal cell carcinoma, Sunitinib.
Shares Savolitinib, Hutchmed, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Savolitinib, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Papillary renal cell carcinoma, Renal cell carcinoma and the tag pipeline.
Shares Savolitinib, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Sunitinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors and the tag pipeline.
Shares Anti-angiogenic therapy, Renal cell carcinoma, Small-molecule kinase inhibitors and the tag pipeline.
Shares Sunitinib, Renal cell carcinoma and the tag pipeline.